Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2021 / Jun / Standardizing CYP2D6 Genotype Testing
Genetics and epigenetics Guidelines and Recommendations Regulation and standards

Standardizing CYP2D6 Genotype Testing

New recommendations from the Association of Molecular Pathology for CYP2D6 genotyping

By Liv Gaskill 06/25/2021 Quick Read (pre 2022) 1 min read

Share

The Association of Molecular Pathology (AMP) Pharmacogenomics (PGx) Working Group has published recommendations for alleles to be included in CYP2D6 clinical genotyping assays (1). Most clinical laboratories undertaking CYP2D6 PGx take a targeted genotyping approach; however, this presents a challenge in CYP2D6 due to its number of alleles and structural variants.

In the AMP recommendations, alleles are divided into a two-tier categorization system – those in Tier 1 are recommended to be included in all CYP2D6 genotype testing as a minimum panel; Tier 2 includes alleles that did not meet all the inclusion criteria for Tier 1 and may be included as additional alleles for testing.

The following inclusion criteria were set for Tier 1 variant alleles:

  1. Have a well-characterized effect on the function of the protein and/or gene expression
  2. Have an appreciable minor allele frequency in a population/ethnicity group
  3. Have publicly available reference materials

Alleles that met all three criteria were included in Tier 1. On the other hand, Tier 2 variant alleles meet at least one of the above criteria, but not all, and can be moved to Tier 1 if additional information or reference materials become available. The recommendations are meant to be a reference guide for labs, rather than restrictive rules, with the goal of promoting standardization of CYP2D6 PGx testing across labs and, in turn, improving patient care.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. VM Pratt et al., J Mol Diag, [Online ahead of print] (2021). PMID: 34118403.

About the Author(s)

Liv Gaskill

During my undergraduate degree in psychology and Master’s in neuroimaging for clinical and cognitive neuroscience, I realized the tasks my classmates found tedious – writing essays, editing, proofreading – were the ones that gave me the greatest satisfaction. I quickly gathered that rambling on about science in the bar wasn’t exactly riveting for my non-scientist friends, so my thoughts turned to a career in science writing. At Texere, I get to craft science into stories, interact with international experts, and engage with readers who love science just as much as I do.

More Articles by Liv Gaskill

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Breathing New Life into Diagnostics
Genetics and epigenetics
Breathing New Life into Diagnostics

January 22, 2024

6 min read

Jonathan Edgeworth on how metagenomics could transform testing for respiratory infections

Molecular Spectacular
Genetics and epigenetics
Molecular Spectacular

January 8, 2024

1 min read

A look at last year’s most interesting molecular pathology stories

Redefining Diagnostic Reference Standards
Genetics and epigenetics
Redefining Diagnostic Reference Standards

January 3, 2022

1 min read

Find out what Horizon Discovery’s diagnostic reference standards can do for your workflow

Defining the Next Generation of NGS
Genetics and epigenetics
Defining the Next Generation of NGS

December 31, 2021

1 min read

Overcoming challenges of the typical NGS workflow with the Ion Torrent™ Genexus™ System

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.